IL314581A - Treatment methods using P-TAU181 LEVEL - Google Patents

Treatment methods using P-TAU181 LEVEL

Info

Publication number
IL314581A
IL314581A IL314581A IL31458124A IL314581A IL 314581 A IL314581 A IL 314581A IL 314581 A IL314581 A IL 314581A IL 31458124 A IL31458124 A IL 31458124A IL 314581 A IL314581 A IL 314581A
Authority
IL
Israel
Prior art keywords
tau181
treatment
methods
level
tau181 level
Prior art date
Application number
IL314581A
Other languages
English (en)
Hebrew (he)
Inventor
Akihiko Koyama
Michael Irizarry
Michio KANEKIYO
Lynn Kramer
June Kaplow
David Verbel
Shobha Dhadda
Pallavi Sachdev
Larisa Reyderman
Seiichi Hayato
Ishani Landry
Robert Gordon
Chad Swanson
Original Assignee
Eisai R&D Man Co Ltd
Akihiko Koyama
Michael Irizarry
Michio KANEKIYO
Lynn Kramer
June Kaplow
David Verbel
Shobha Dhadda
Pallavi Sachdev
Larisa Reyderman
Seiichi Hayato
Ishani Landry
Robert Gordon
Chad Swanson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd, Akihiko Koyama, Michael Irizarry, Michio KANEKIYO, Lynn Kramer, June Kaplow, David Verbel, Shobha Dhadda, Pallavi Sachdev, Larisa Reyderman, Seiichi Hayato, Ishani Landry, Robert Gordon, Chad Swanson filed Critical Eisai R&D Man Co Ltd
Publication of IL314581A publication Critical patent/IL314581A/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
IL314581A 2022-02-02 2022-11-09 Treatment methods using P-TAU181 LEVEL IL314581A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263306060P 2022-02-02 2022-02-02
US202263269394P 2022-03-15 2022-03-15
US202263364617P 2022-05-12 2022-05-12
PCT/US2022/079571 WO2023149970A1 (en) 2022-02-02 2022-11-09 Methods of treatment using p-tau181 level

Publications (1)

Publication Number Publication Date
IL314581A true IL314581A (en) 2024-09-01

Family

ID=84488881

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314581A IL314581A (en) 2022-02-02 2022-11-09 Treatment methods using P-TAU181 LEVEL

Country Status (11)

Country Link
US (1) US20250377367A1 (https=)
EP (1) EP4473009A1 (https=)
JP (1) JP2025506389A (https=)
KR (1) KR20240142535A (https=)
AU (1) AU2022439338A1 (https=)
CA (1) CA3243435A1 (https=)
CL (1) CL2024002309A1 (https=)
IL (1) IL314581A (https=)
MX (1) MX2024009492A (https=)
TW (1) TW202339794A (https=)
WO (1) WO2023149970A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025260029A1 (en) * 2024-06-14 2025-12-18 Eisai R&D Management Co., Ltd. Method for quantifying amyloid beta protofibril
CN118777453B (zh) * 2024-06-25 2025-04-08 上海交通大学医学院附属瑞金医院 一种基于液相色谱-串联质谱定量分析血液中仑卡奈单抗浓度的方法
WO2026015877A1 (en) 2024-07-12 2026-01-15 Eisai R&D Management Co., Ltd. Fluid biomarker

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2414772C (en) 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
LT2448968T (lt) 2009-06-29 2021-05-10 Bioarctic Ab Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus
JP5894939B2 (ja) 2010-02-26 2016-03-30 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用
WO2016005466A2 (en) 2014-07-10 2016-01-14 Bioarctic Neuroscience Ab IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
AU2018352308B2 (en) 2017-10-16 2025-06-05 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
US20210324056A1 (en) * 2018-07-24 2021-10-21 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease
KR20220084095A (ko) * 2019-10-22 2022-06-21 바이오젠 엠에이 인코포레이티드 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체
RS67249B1 (sr) 2020-03-20 2025-10-31 Eisai R&D Man Co Ltd Formulacije antitela visoke koncentracije protiv protofibrila amiloid beta peptida i metode njihove upotrebe

Also Published As

Publication number Publication date
CL2024002309A1 (es) 2025-01-24
KR20240142535A (ko) 2024-09-30
TW202339794A (zh) 2023-10-16
CA3243435A1 (en) 2023-08-10
JP2025506389A (ja) 2025-03-11
US20250377367A1 (en) 2025-12-11
AU2022439338A1 (en) 2024-08-15
MX2024009492A (es) 2024-08-09
WO2023149970A1 (en) 2023-08-10
EP4473009A1 (en) 2024-12-11

Similar Documents

Publication Publication Date Title
IL314581A (en) Treatment methods using P-TAU181 LEVEL
IL315503A (en) Treatment methods
IL320711A (en) Treatment methods
ZA202206163B (en) Methods of treating coronavirus
IL290983A (en) Treatment methods
IL287250A (en) treatment method
GB202201824D0 (en) Methods of treatment
GB202201825D0 (en) Methods of treatment
GB202201819D0 (en) Methods of treatment
GB201918853D0 (en) Methods of treatment
IL325944A (en) Treatment methods
HK40117335A (en) Methods of treatment using p-tau181 level
IL321175A (en) Treatment methods with tardifitant
GB202118011D0 (en) Methods of treatment
GB202118007D0 (en) Methods of treatment
GB202118006D0 (en) Methods of treatment
IL268111A (en) Methods of treating pain
GB202108245D0 (en) Methods of treatment
GB202108242D0 (en) Methods of treatment
GB202202876D0 (en) Method of treatment
GB202315695D0 (en) TReatment of cariomyopathy
GB202212506D0 (en) Treatment of covid-19
GB202005874D0 (en) Methods of treatment
GB202201833D0 (en) Method of water treatment
GB202506231D0 (en) Methods of treatment